VENTURA COUNTY
HEALTH CARE PLAN

Ilaris (canakinumab)

Effective Date: 10/22/13
Date Developed: 9/3/13 by Albert Reeves MD
Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19
(Archived 1/22/19)

Pharmacologic Cagegory: Ilaris is a recombinant, human anti-human-IL-1β monoclonal IgG antibody

Pre-Authorization Criteria:

VCHCP will authorize Elaris for 1) Systemic Idiopathic Juvenile Arthritis in patients two years and older; 2) Cryopyrin-associated periodic syndromes (CAPS; very rare genetic syndromes manifested by excessive inflammation)

Dosing: 4mg/kg (body weight greater than 7.5 kg) subcutaneously every four weeks

PRECAUTIONS: increased risk of infections (especially upper respiratory tract); possible reactivation of latent tuberculosis; hypersensitivity; Macrophage Activation Syndrome (MAS; severe systemic reaction resulting from uncontrolled activation and proliferation of macrophages and T lymphocytes)

DRUG INTERACTIONS: enhanced effects of other immunosuppressants; diminished therapeutic effect of inactivated and enhanced adverse effects of live vaccines

REFERENCES

Grom AA, Mellins ED (September 2010). "Macrophage activation syndrome: advances towards understanding pathogenesis". *Curr Opin Rheumatol* **22** (5): 561–6.

Ruperto N, Brunner HI, Quartier P, et al, "Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis," *N Engl J Med*, 2012, 367(25):2396-406.

Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, et al, "Canakinumab in CAPS Study Group. Sustained Remission of Symptoms and Improved Health-Related Quality of Life in Patients With Cryopyrin-Associated Periodic Syndrome Treated With Canakinumab: Results of a Double-Blind Placebo-Controlled Randomized Withdrawal Study," *Arthritis Res Ther*, 2011, 13(6):R202.

Revision History:

Date Approved by P&T Committee: 10/22/13
Date Reviewed/No Updates: 1/28/14 by C. Sanders MD
Date Approved by P&T Committee: 1/28/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – check ESI